التفاصيل البيبلوغرافية
| العنوان: |
Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720. |
| المؤلفون: |
Baer, M. R., George, S. L., Sanford, B. L., Mrózek, K., Kolitz, J. E., Moore, J. O., Stone, R. M., Powell, B. L., Caligiuri, M. A., Bloomfield, C. D., Larson, R. A., Mrózek, K, Cancer and Leukemia Group B |
| المصدر: |
Leukemia (08876924); May2011, Vol. 25 Issue 5, p800-807, 8p, 4 Charts, 2 Graphs |
| مصطلحات موضوعية: |
ETOPOSIDE, MYELOID leukemia, DRUG therapy, CYTARABINE, KARYOTYPES, MULTIVARIATE analysis, PATIENTS, ANTINEOPLASTIC agents, DAUNOMYCIN, COMPARATIVE studies, RESEARCH methodology, MEDICAL cooperation, RESEARCH, SURVIVAL, EVALUATION research, ACUTE myeloid leukemia, TREATMENT effectiveness, DISEASE remission, THERAPEUTICS |
| مستخلص: |
Untreated de novo (n=421) and secondary (n=189) acute myeloid leukemia (AML) patients ≥60 years received intensified chemotherapy, including daunorubicin 60 mg/m(2) and etoposide 100 mg/m(2) during days 1, 2, 3 with cytarabine 100 mg/m(2) during days 1-7, with a second induction if needed and one consolidation course with these drugs and doses for 2, 2 and 5 days, respectively. In all, 287 (47%) achieved complete remission (CR), 136 (22%) died and 187 (31%) were non-responders. CR rates were 27, 44 and 52% for complex karyotypes, rare aberrations and neither (P<0.001), 52 and 37% for de novo and secondary AML (P=0.003), and 53 and 42% for age 60-69 and ≥70 years (P=0.015). In multivariable analysis, CR predictors included non-complex/non-rare karyotypes (P<0.001), de novo AML (P<0.001), better performance status (PS) (P<0.001) and younger age (P=0.001). Disease-free (DFS) and overall (OS) survival medians were 6.8 (95% CI: 6.2, 7.8) and 7.2 (95% CI: 6.4, 8.6) months. In multivariable analysis, DFS was shorter for complex karyotypes (P<0.001) and increasing white blood count (WBC) (P<0.001) and age (P=0.038), and OS for complex karyotypes (P<0.001), increasing WBC (P=0.001) and age (P<0.001), poorer PS (P<0.001) and secondary AML (P=0.010). Outcomes and prognostic factors were similar to those in previous Cancer and Leukemia Group B studies. [ABSTRACT FROM AUTHOR] |
|
Copyright of Leukemia (08876924) is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder